{"id":"W3176859254","doi":"10.1158/1538-7445.am2021-lb040","title":"Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Immune checkpoint; Interim analysis; Adverse effect; Immunotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001793901,0.001285496,0.001675852,0.0004092679,0.0003463054,0.0009950665,0.0008264388,0.0009794515,0.00265909],"category_scores_gemma":[0.0008184482,0.0005701758,0.001141371,0.0004856104,0.000946897,0.0008868876,0.0004303805,0.002507635,0.0008591564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009771093,"about_ca_system_score_gemma":0.001525642,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008792392,"about_ca_topic_score_gemma":0.001198946,"domain_scores_codex":[0.9995031,0.0002697618,0.00002904689,0.00007412249,0.00004846148,0.00007541823],"domain_scores_gemma":[0.9994448,0.00007104135,0.0001172186,0.00003924683,0.00004246153,0.0002852458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7022184,0.08540772,0.009601812,0.0006237424,0.001292063,0.0002482006,0.000309002,0.002132752,0.08252854,0.0002189015,0.003864848,0.111554],"study_design_scores_gemma":[0.2915176,0.686179,0.01292027,0.00003018221,0.0005439175,0.0002478466,0.00005716195,0.001219428,0.004888011,0.0001161905,0.002254548,0.00002582779],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960622,0.001716767,0.0003441217,0.0002665262,0.00004860218,0.0004950133,0.0004193102,0.00008289758,0.0005645624],"genre_scores_gemma":[0.9929131,0.001236919,0.001593651,0.0005308831,0.0001718801,0.0008188221,0.001565753,0.00002605349,0.001143071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00265909,"threshold_uncertainty_score":0.009487212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08120297173712268,"score_gpt":0.412915772642964,"score_spread":0.3317128009058413,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}